Blood biomarkers for assessment of mild traumatic brain injury and chronic traumatic encephalopathy

Biomarkers ◽  
2020 ◽  
Vol 25 (3) ◽  
pp. 213-227 ◽  
Author(s):  
Matthew I. Hiskens ◽  
Anthony G. Schneiders ◽  
Mariana Angoa-Pérez ◽  
Rebecca K. Vella ◽  
Andrew S. Fenning
2019 ◽  
Vol 51 (Supplement) ◽  
pp. 740
Author(s):  
Eunhan Cho ◽  
Nathan Lemoine ◽  
Bailey Theall ◽  
Amy Turner ◽  
Jack Marucci ◽  
...  

2018 ◽  
Vol 120 (1) ◽  
pp. 1-3
Author(s):  
Megan E. Huibregtse

Chronic traumatic encephalopathy (CTE) is thought to be caused by repetitive head impacts. Consequently, there is a need to develop rodent models to better understand the behavioral and pathophysiological changes of repetitive mild traumatic brain injury (rmTBI) and to determine the link between rmTBI and CTE. This Neuro Forum article reviews recent rodent rmTBI models, comparing the impact methods and outcome measures in terms of translational potential.


2021 ◽  
Author(s):  
V. Sapin ◽  
R. Gaulmin ◽  
R. Aubin ◽  
S. Walrand ◽  
A. Coste ◽  
...  

2016 ◽  
Vol 33 (1) ◽  
pp. 49-57 ◽  
Author(s):  
Rongzi Shan ◽  
Joanna Szmydynger-Chodobska ◽  
Otis U. Warren ◽  
Farah Mohammad ◽  
Brian J. Zink ◽  
...  

2014 ◽  
Vol 31 (13) ◽  
pp. 1211-1224 ◽  
Author(s):  
Anthony L. Petraglia ◽  
Benjamin A. Plog ◽  
Samantha Dayawansa ◽  
Michael Chen ◽  
Matthew L. Dashnaw ◽  
...  

Neurology ◽  
2017 ◽  
Vol 89 (6) ◽  
pp. 623-632 ◽  
Author(s):  
Andrew R. Mayer ◽  
Davin K. Quinn ◽  
Christina L. Master

Objective:This review provides an in-depth overview of diagnostic schema and risk factors influencing recovery during the acute, subacute (operationally defined as up to 3 months postinjury), and chronic injury phases across the full spectrum of individuals (e.g., athletes to neurosurgery patients) with mild traumatic brain injury (mTBI). Particular emphasis is placed on the complex differential diagnoses for patients with prolonged postconcussive symptoms.Methods:Select literature review and synthesis.Results:In spite of an increase in public awareness surrounding the acute and potential long-term effects of mTBI, the medical field remains fragmented both in terms of the diagnostic (different criteria proffered by multiple medical organizations) and prognostic factors that influence patient care.Conclusions:Given the lack of objective biomarkers and the spectrum of different disorders that likely encompass mTBI, clinicians are encouraged to adopt a probabilistic, rather than definitive, diagnostic and prognostic framework. The relevance of accurately diagnosing and managing the different manifestations of mTBI becomes clear when one considers the overall incidence of the disorder (42 million people each year worldwide), and the different treatment implications for patients with a true neurodegenerative disorder (e.g., chronic traumatic encephalopathy; rare) vs potentially treatable conditions (e.g., depression or posttraumatic headache; frequent).


2020 ◽  
Vol 85 ◽  
pp. 5-11
Author(s):  
Damien Bouvier ◽  
Charlotte Oris ◽  
Marina Brailova ◽  
Julie Durif ◽  
Vincent Sapin

Sign in / Sign up

Export Citation Format

Share Document